Aralez rockets on Yosprala approval from FDA

15 September 2016

Shares in Canada-based specialty pharma company Aralez Pharmaceuticals (TSX: ARLZ) were up more than 9% on Thursday lunchtime after the US Food and Drug Administration approved once-daily Yosprala (aspirin/omeprazole).

Yosprala is indicated for secondary prevention of cardiovascular and cerebrovascular events in patients at risk for aspirin-associated gastric ulcers. It is now the only prescription fixed-dose combination of aspirin, an anti-platelet agent, and omeprazole, a proton pump inhibitor (PPI) in the USA.

Aralez is expanding its sales force in the USA by 85 representatives this month, taking it to a total of 110, and plans to begin the promotional US launch of Yosprala during the first week of October.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK